Leo Pharma looks towards billion-dollar market after phase III success
If everything goes to plan, Leo Pharma will become the second company in the world to lauch a biological drug against eczema. Research director Kim Kjøller has big expectations for the drug, which will compete with Sanofi’s blockbuster drug Dupixent.
Wednesday’s positive data for the eczema drug tralokinumab has given Leo Pharma a pat on the back for its relatively new gamble on biological medicines.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
